Stage IIIB Cutaneous Melanoma AJCC v7 Recruiting Phase 0 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)Recruiting0
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03276832Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV MelanomaTreatment